AstraZeneca Canada Inc. operates as a biopharmaceutical company that engages in discovering, developing, manufacturing, marketing, and selling prescription medicines in Canada. It focuses on various therapeutic areas, such as cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory. The company was founded in 1999 and is based in Mississauga, Canada. Astrazeneca Canada Inc. operates as a subsidiary of AstraZeneca PLC.
1004 Middlegate Road
Mississauga, ON L4Y 1M4
Founded in 1999
AstraZeneca Announces Initiation of Two Additional Global Studies for BRILINTA (ticagrelor)
Dec 5 13
AstraZeneca has announced plans to conduct two new Phase IIIb clinical studies as part of PARTHENON, the company's clinical trial programme involving over 80,000 patients, with Canada actively participating in both studies. The studies are designed to build scientific understanding of BRILINTA (ticagrelor) tablets in additional high-risk patient populations. SOCRATES (Acute Stroke Or Transient IsChaemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES) is a global clinical trial involving 9,600 patients who have experienced an acute ischaemic stroke or transient ischaemic attack (TIA). Ischaemic strokes occur as a result of an obstruction of a vessel supplying blood to the brain. A TIA is secondary to a temporary insufficient blood supply to parts of the brain and is often considered a warning sign that a stroke may follow. SOCRATES is a randomized, parallel group study evaluating the efficacy of ticagrelor compared to aspirin in reducing major vascular events (composite of all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke) in patients with acute ischaemic stroke (NIHSS < 5). THEMIS (Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study) is a global clinical trial involving 17,000 patients with Type 2 diabetes at high risk of cardiovascular events. More than nine million Canadians are currently living with diabetes or pre-diabetes(4) and approximately 90% of those affected are Type 2. THEMIS is an event-driven, randomised, parallel group study comparing the efficacy of long-term treatment with ticagrelor versus placebo for the prevention of major cardiovascular events (composite of cardiovascular death, myocardial infarction or stroke) in patients with Type 2 diabetes without a history of previous myocardial infarction or stroke, but with documented coronary atherosclerosis. Study patients will receive ticagrelor 90 mg twice daily versus placebo and will be managed according to local standards of care, including provision of dietary and lifestyle advice according to local diabetes treatment guidelines. Use of low-dose aspirin once daily is permitted if clinically indicated, as judged by the investigator. SOCRATES and THEMIS will be monitored by Independent Data Monitoring Committees who will review the safety and efficacy of treatments in these trials. The trials will be conducted in accordance with Good Clinical Practice. Both studies will be posted on clinicaltrials.gov in the near future. AstraZeneca is currently collaborating with over 4,000 clinical investigators in more than 30 countries as part of the PARTHENON programme, and has established partnerships with a number of pre-eminent research institutions. Other studies in the PARTHENON programme include PEGASUS, studying ticagrelor for secondary prevention in patients with previous myocardial infarction, and EUCLID studying patients with Peripheral Artery Disease. PARTHENON will provide a huge dataset to build scientific understanding of ticagrelor in a broad a range of atherothrombotic conditions. Ticagrelor is currently not approved for the treatment of patients with ischaemic stroke, Peripheral Artery Disease, or for secondary prevention in patients with a history of previous myocardial infarction going back more than one year.
AstraZeneca Canada Inc. Continues to Support Patients on CRESTOR
May 29 12
AstraZeneca Canada Inc. announced it modifies the recently launched Crestor Prescription Benefit cards to cover the difference in cost between brand Crestor and generic rosuvastatin calcium, enabling physician, pharmacist and patient choice. STI and AstraZeneca launched Prescription Benefit cards across Canada in February providing a financial benefit for Crestor patients in order to improve adherence. All current and future Crestor cards will now provide an additional benefit to cover the difference in cost between generic and brand. To provide instant access to the program, AstraZeneca has also launched a website where physicians, pharmacists and patients can download a card (crestorsupport.ca). STI programs provide continuity of care and improve adherence for patients taking these medications. The Crestor Prescription Benefit Program is currently available across Canada, except the provinces of Quebec and Manitoba, and must be accompanied by a prescription.